Retaining AngioDynamics At Neutral
We reaffirm our Neutral recommendation for therapeutic and diagnostic devices maker AngioDynamics (NASDAQ:ANGO) following its second-quarter fiscal 2012 results. The company’s adjusted earnings of 13 cents a share beat the Zacks Consensus Estimate by a penny. Revenues climbed 9% year over year to $58.1 million, topping the Zacks Consensus Estimate of $56 million. However, profits [...]
We reaffirm our Neutral recommendation for therapeutic and diagnostic devices maker AngioDynamics (NASDAQ:ANGO) following its second-quarter fiscal 2012 results. The company’s adjusted earnings of 13 cents a share beat the Zacks Consensus Estimate by a penny. Revenues climbed 9% year over year to $58.1 million, topping the Zacks Consensus Estimate of $56 million.
However, profits tanked 29% year over year on account of charges associated with CEO departure and the closure of the company’s U.K. … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards
